LONDON, March 19, 2014 /PRNewswire/ --
On Tuesday, March 18, 2014, the
NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500
advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average
closed at 16,336.19, up 0.55%. The gains were broad based as nine
out of ten sectors ended the session in positive. The S&P 500
Health Care Sector Index finished the day at 688.96, up 1.17%, and
the same has advanced 1.47% in the last one month. Investor-Edge
has initiated coverage on the following equities: Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals Inc.
(NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc.
(NASDAQ: IPXL). Free technical research on KERX, RIGL, SNY and IPXL
can be downloaded upon signing up at:
http://www.investor-edge.com/336-register
On Tuesday, shares in Keryx Biopharmaceuticals Inc. surged 3.07%
to close at $15.45. A total of 1.45
million shares were traded, which is below the three months average
volume of 2.83 million. The company's shares oscillated between
$15.04 and $15.51 during the trading
session. Keryx's shares has fallen by 0.96% in the last one month,
while the same has gained 1.71% in the previous three trading
session and 19.31% on YTD basis. The company's shares are trading
above their 50-day and 200-day moving averages. Keryx
Biopharmaceuticals Inc.'s 50-day moving average of $15.04 is above the 200-day moving average of
$11.29. Furthermore, the company's
stock is trading at the Relative Strength Index (RSI) of 44.63.
Sign up today to read free research on KERX at:
http://www.investor-edge.com/336-KERX-19Mar2014.pdf
Shares in Rigel Pharmaceuticals Inc. recorded a trading volume
of 1.57 million shares, as compared with a three months average
volume of 1.12 million shares. The stock ended the day at
$4.70, up 5.62% after vacillating
between $4.40 and $4.80. Rigel
Pharmaceuticals Inc.'s shares have rallied 17.21% in the previous
three trading sessions, 47.34% in the last one month, and 64.91% on
YTD basis. The company's shares are trading above their 50-day and
200-days moving averages. Rigel Pharmaceuticals Inc.'s 50-day
moving average of $3.46 is above the
200-day moving average of $3.38.
Additionally, shares of the company are trading at the Relative
Strength Index (RSI) of 62.85. Sign up today to read free research
on RIGL at:
http://www.investor-edge.com/336-RIGL-19Mar2014.pdf
On Tuesday, Sanofi's stock edged 0.68% higher, finishing the
session at $50.41. The stock recorded
trading volume of 2.18 million shares as compared to a three months
average volume of 1.67 million shares. The stock fluctuated between
$50.21 and $50.68 during the session.
Sanofi's shares have advanced 1.41% in the previous three trading
session, while the same has fallen by 0.04% in the last one month
and 6.00% on YTD basis. The company's shares are trading below
their 50-day and 200-day moving averages. Sanofi's 200-day moving
average of $51.20 is above the 50-day
moving average of $50.46. Moreover,
the stock is trading at the Relative Strength Index (RSI) of 44.86.
Sign up today to read free research on SNY at:
http://www.investor-edge.com/336-SNY-19Mar2014.pdf
Shares in Impax Laboratories Inc. saw a trading volume of 0.59
million shares, as compared with a three months average volume of
0.57 million shares. The stock ended the day at $27.84, down 0.25% and at an intraday range of
$27.58 and $28.05. Shares of the company traded at a PE
ratio of 28.84. Impax Laboratories Inc.'s shares have gained 5.02%
in the previous three trading sessions, 16.88% in the last one
month, and 10.74% on YTD basis. The stock is trading above its
50-day and 200-day moving averages. Impax Laboratories Inc.'s
50-day moving average of $24.76 is
above the 200-day moving average of $22.04. Furthermore, the stock is trading at the
Relative Strength Index (RSI) of 67.67. Sign up today to read free
research on IPXL at:
http://www.investor-edge.com/336-IPXL-19Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and
our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by
our team, or wish to learn more about our services, please contact
us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.investor-edge.com/
SOURCE Investor-Edge